Zaitseva M B, Moshnikov S A, Kozhich A T, Frolova H A, Makarova O D, Pavlikov S P, Sidorovich I G, Brondz B B
All-Union Cancer Research Center, Academy of Medical Sciences, Moscow, USSR.
Scand J Immunol. 1992 Mar;35(3):267-73. doi: 10.1111/j.1365-3083.1992.tb02858.x.
Seventy-five per cent of sera from HIV-1-infected individuals bind to the human B-lymphoma cells bearing the major histocompatibility class II molecule in enzyme-linked immunosorbent assay (ELISA). The binding is caused by the antibodies against the class II molecule present in the serum samples which prevent the interaction of murine anti-HLA.DR monoclonal antibody with B lymphoma in FACS analysis. The three highly conserved amino acid sequences in alpha- and beta-chains of the class II molecule and three homologous fragments in HIV-1 gp120 and gp41 were identified by computer search and synthesized. Using these peptides it was demonstrated that 28-48% of HIV-positive sera contain antibodies that cross-react with the peptide of HIV-1 origin and with the peptide from the class II molecule as well.
在酶联免疫吸附测定（ELISA）中，75%来自HIV-1感染个体的血清能与携带主要组织相容性复合体II类分子的人B淋巴瘤细胞结合。这种结合是由血清样本中针对II类分子的抗体引起的，在荧光激活细胞分选分析（FACS）中，这些抗体可阻止鼠抗HLA.DR单克隆抗体与B淋巴瘤细胞相互作用。通过计算机搜索确定了II类分子α链和β链中的三个高度保守氨基酸序列以及HIV-1 gp120和gp41中的三个同源片段，并进行了合成。使用这些肽段证明，28%-48%的HIV阳性血清含有与HIV-1来源肽段以及II类分子肽段都发生交叉反应的抗体。
